By Sabela Ojea


Vanda Pharmaceuticals said the Food and Drug Administration approved fanapt to treat manic or mixed episodes associated with bipolar I disorder in adults.

The biopharmaceutical company on Tuesday said the marketing approval of Fanapt for bipolar I disorder patients significantly increases the commercial opportunity of the treatment.

Bipolar disorder affects about 2.8% of the total U.S. adult population, the company said.

Fanapt has been used for the acute treatment of patients with schizophrenia since its FDA approval in 2009.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

04-02-24 1841ET